Heron Therapeutics, Inc.
$1.05
▼
-0.54%
2026-04-21 07:21:01
www.herontx.com
NCM: HRTX
Explore Heron Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$187.09 M
Current Price
$1.05
52W High / Low
$2.61 / $0.74
Stock P/E
—
Book Value
$0.07
Dividend Yield
—
ROCE
-1.59%
ROE
209.08%
Face Value
—
EPS
$-0.12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
128
Beta
1.42
Debt / Equity
981.22
Current Ratio
2.48
Quick Ratio
1.51
Forward P/E
1.67
Price / Sales
1.04
Enterprise Value
$255.88 M
EV / EBITDA
-1,142.32
EV / Revenue
1.65
Rating
Strong Buy
Target Price
$4.33
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Biomea Fusion, Inc. | $2.05 | — | $159.78 M | — | -171.28% | -1.52% | $3.08 / $0.87 | $0.41 |
| 2. | Gain Therapeutics, Inc. | $2.12 | — | $89.98 M | — | -96.12% | -1.56% | $4.34 / $1.41 | $0.44 |
| 3. | Kymera Therapeutics, Inc. | $88.84 | — | $7.31 B | — | -20.82% | -25.78% | $103 / $24.43 | $19.42 |
| 4. | vTv Therapeutics Inc. | $37.75 | — | $157.78 M | — | -39.41% | -78.94% | $44 / $14 | $5.19 |
| 5. | Summit Therapeutics Inc. | $24.32 | — | $18.91 B | — | -161.37% | -2.06% | $36.91 / $13.83 | $0.85 |
| 6. | MannKind Corporation | $2.92 | 135.49 | $907.36 M | — | 7.49% | -9.03% | $6.51 / $2.23 | $-0.17 |
| 7. | Cognition Therapeutics, Inc. | $1.12 | — | $106.33 M | — | -70.77% | -88.59% | $3.83 / $0.22 | $0.39 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 40.59 M | 38.21 M | 37.2 M | 38.9 M | 40.78 M |
| Operating Profit | 0.04 M | -4.09 M | -1.64 M | 3.15 M | 4.17 M |
| Net Profit | -2.95 M | -17.5 M | -2.38 M | 2.63 M | 3.66 M |
| EPS in Rs | -0.02 | -0.09 | -0.01 | 0.01 | 0.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 154.9 M | 144.28 M | 127.04 M | 107.67 M |
| Operating Profit | -2.54 M | -11.53 M | -110.61 M | -174.66 M |
| Net Profit | -20.2 M | -13.58 M | -110.56 M | -182.02 M |
| EPS in Rs | -0.11 | -0.07 | -0.59 | -0.97 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 255.88 M | 233.15 M | 222.51 M | 250.95 M |
| Total Liabilities | 241.54 M | 266.8 M | 256.48 M | 237.38 M |
| Equity | 14.33 M | -33.65 M | -33.97 M | 13.57 M |
| Current Assets | 238.07 M | 209.01 M | 188.77 M | 205.44 M |
| Current Liabilities | 96.1 M | 91.46 M | 79.69 M | 82.36 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -27.59 M | -22.53 M | -58.79 M | -146.91 M |
| Investing CF | 16.01 M | 18.71 M | 18 M | -3.32 M |
| Financing CF | 14.43 M | 0.94 M | 54.11 M | 75.06 M |
| Free CF | -27.91 M | -24.23 M | -60.33 M | -148.74 M |
| Capex | -0.32 M | -1.71 M | -1.54 M | -1.82 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 13.57% | 17.99% | — | — |
| Earnings Growth % | 87.72% | 39.26% | — | — |
| Profit Margin % | -9.41% | -87.02% | -169.05% | — |
| Operating Margin % | -7.99% | -87.07% | -162.21% | — |
| Gross Margin % | 73.21% | 48.75% | 49.04% | — |
| EBITDA Margin % | -3.5% | -81.7% | -164.07% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.